Skip to main content
Drug Design, Development and Therapy logoLink to Drug Design, Development and Therapy
. 2014 May 21;8:569. doi: 10.2147/DDDT.S58818

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

PMCID: PMC4035248

Novakovic D, Feligioni M, Scaccianoce S, et al. Drug Des Devel Ther. 2013;7:1359–1364.

On page 1362, left hand column, last sentence under Functional studies:

The effects of gantenerumab on cognitive assessment in the Morris water maze test were inconclusive, as both wild-type and transgenic AD mice injected with vehicle displayed impairment of learning, which might be ascribed to stress conditions caused by weekly intracerebroventricular injections. Importantly, neurological or motor impairments were not detected even after 5 months of treatment.24

Should read as:

The effects of gantenerumab on cognitive assessment in the Morris water maze test were inconclusive, as both wild-type and transgenic AD mice injected with vehicle displayed impairment of learning, which might be ascribed to stress conditions caused by weekly intravenous injections. Importantly, neurological or motor impairments were not detected even after 5 months of treatment.24


Articles from Drug Design, Development and Therapy are provided here courtesy of Dove Press

RESOURCES